Wockhardt gets CDSCO nod for Zaynich antibiotic

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potential against drug-resistant bacteria. This marks a significant step in combating challenging infections.